Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

5(71.4%)

Phase 1

1(14.3%)

Early Phase 1

1(14.3%)

7Total

N/A(5)

Phase 1(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03595722Not ApplicableUnknown

Exploring HIFU as a Treatment for Rectal and Other Pelvic Cancers

Role: collaborator

NCT02756884Early Phase 1Completed

Safety and Preliminary Efficacy of Adipose Derived Stem Cells and Low Frequency Ultrasound in PAD

Role: collaborator

NCT00573586Not ApplicableUnknown

Treatment of Localized Prostate Cancer With High Intensity Focused Ultrasound Using the Sonablate® 500 System in Canada

Role: lead

NCT00772317Not ApplicableUnknown

A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)

Role: lead

NCT00770822Not ApplicableUnknown

Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer

Role: lead

NCT00537849Not ApplicableWithdrawn

Investigational Study For the Treatment of Localized (T1c/T2a) Prostate Cancer With High Intensity Focused Ultrasound (HIFU) Using the Sonablate 500 (SB-500) System in Canada

Role: lead

NCT02248389Phase 1Completed

Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses

Role: collaborator

All 7 trials loaded